TP53 and myeloid neoplasm: Further, using NGS in a subgroup of patients, our data reveal that our patient population, irrespective of response pattern, is enriched for a broad spectrum of mutations in myeloid malignancy associated genes with a unique TP53 signature detected in the non-responding patient subset.